Last Updated : November 17, 2017
Details
FilesGeneric Name:
Dabrafenib & Trametinib in combo
Project Status:
Complete
Therapeutic Area:
Non-Small Cell Lung Cancer
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Tafinlar & Mekinist in combo
Project Line:
Reimbursement Review
Project Number:
PC0106-000
NOC Status at Filing:
Pre NOC
Strength:
Dabrafenib: 50mg and 75mg capsules; Trametinib: 0.5mg and 2.0mg tablet
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer
Funding Request:
In combination for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have been previously treated with chemotherapy
Pre Noc Submission:
Yes
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : November 17, 2017